August 2021 in “The Journal of Urology” This study found a significant association between finasteride use and reports of sexual dysfunction, particularly greater in young men using it for alopecia compared to older BPH patients.
June 2025 in “Frontiers in Neurology” This study found a significant association between finasteride use and increased risk of memory impairment, highlighting the need for risk communication and routine cognitive monitoring for long-term users.
76 citations
,
May 2020 in “Ultraschall in der Medizin - European Journal of Ultrasound” This consensus document provides foundational position statements for dermatologic ultrasound but reports no clinical results; it aims to guide future evidence-based recommendations and guidelines.
15 citations
,
January 2017 in “Experimental Neurology” This study found that finasteride significantly reduced levodopa-induced dyskinesia in both male and female rats without diminishing l-DOPA's motor benefits, indicating potential for clinical trials in Parkinson's patients.
December 2025 in “The AAPS Journal” Finasteride and dutasteride's effects are mainly due to target binding saturation and slow enzyme turnover.
June 2023 in “Zenodo (CERN European Organization for Nuclear Research)” August 2018 in “Journal of the American Academy of Dermatology” 25 citations
,
October 2008 in “Chromatographia” This study developed and validated a sensitive and rapid method to simultaneously measure alfuzosin and dutasteride in human plasma, enabling high-throughput analysis for pharmacokinetic and bioequivalence studies.
27 citations
,
July 2001 in “Journal of Pharmaceutical and Biomedical Analysis” Finasteride remains stable for two years with proper storage.
1 citations
,
September 2024 in “Journal of the American Academy of Dermatology” Farudodstat may effectively treat alopecia areata without harmful side effects.
January 2026 in “Figshare” This table reports gene set enrichment analysis scores for hair follicle compartments across diseases and sampling methods, providing comparisons but no new experimental findings.
April 2024 in “African Journal of Biological Sciences” This case report describes a patient with systemic lupus erythematosus who developed Degos disease and non-scarring alopecia, highlighting dermoscopy's role in diagnosis and treatment prognosis.
April 2026 in “Brain Sciences” This pharmacovigilance study analyzed FAERS data and found that finasteride is more frequently associated with neuropsychiatric reactions like depression and suicide risk, especially in younger men using it for alopecia, compared to dutasteride.
August 2026 in “Fabad Journal of Pharmaceutical Sciences” This study developed a Neusilin® US2-based solid self-nanoemulsifying drug delivery system for finasteride that showed improved stability and drug delivery, with complete dissolution comparable to standard Propecia® tablets.
111 citations
,
June 2015 in “Age and Ageing” This study classified dutasteride, fesoterodine, and finasteride as beneficial for older or frail elderly patients, while suggesting caution or avoidance of α-blockers and antimuscarinics in this group.
January 2017 in “PRISM (University of Calgary)” This study identifies unique gene expression patterns in specialized fibroblasts within adult hair follicles, which advances understanding of their role in tissue regeneration.
26 citations
,
September 2018 in “Neurobiology of Disease” This study found that both finasteride and dutasteride significantly reduced L-DOPA-induced dyskinesia in a rat model of Parkinson's disease, with dutasteride showing greater effectiveness at lower doses.
4 citations
,
December 2021 in “Journal of clinical laboratory analysis” This study identified a splicing-site deletion in the DCAF17 gene associated with Woodhouse-Sakati syndrome in a large consanguineous pedigree, leading to typical phenotypic features.
December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” This policy brief highlights that post-drug syndromes remain under-recognized in pharmacovigilance, leading to inadequate risk assessments and patient care. It identifies systemic failures in current frameworks and recommends actions to improve long-term drug safety monitoring and education, affecting public health outcomes significantly.
September 2018 in “The Journal of Urology” This review discusses FAERS data on 5-alpha reductase inhibitors and their potential implications for post-finasteride syndrome, but it does not report any new clinical results.
4 citations
,
August 2021 in “Pediatrics in review” This review explores disorders of sex development, emphasizing the need for a systematic, multidisciplinary approach and the benefits of genetic testing for better diagnosis and gender assignment planning, but it reports no new clinical findings.
1 citations
,
January 2020 in “Skin appendage disorders” Finasteride may help treat frontal fibrosing alopecia, but more research is needed.
March 2022 in “Institutional Repositories DataBase (IRDB)” This system overview describes the UTokyo Repository's role in storing and providing online access to digital resources from the University of Tokyo, reporting no new empirical findings or research results.
1 citations
,
July 2023 in “Clinical Cosmetic and Investigational Dermatology” In this report, a 54-year-old woman with familial dyskeratotic comedones showed slight improvement in skin lesions after topical retinoids and urea cream. This source also describes the first dermoscopic findings for this condition and reviews 21 previous cases.
1 citations
,
August 2024 in “Expert Opinion on Drug Safety” This study analyzed data from the FDA Adverse Event Reporting System and found that finasteride had the highest reporting frequency and signal strength for drug-induced erectile dysfunction among 734 drugs, with compound preparations posing higher risks than single ingredients.
In this study, finasteride reduced the severity of dopaminergic behavior manifestations in rats without causing extrapyramidal side effects, unlike other antidopaminergic agents.
April 2023 in “Tikrit Journal of Pharmaceutical Sciences” In this study, researchers assessed the effects of deferasirox in 85 children with ß-thalassemia in Kirkuk and reported that while 55.3% experienced a reduction in serum ferritin, 9.4% had adverse effects, indicating that deferasirox is generally well-tolerated as an iron chelator with modifiable side effects.
January 2020 in “Clinical Case Reports and Reviews” This study observed that the coexistence of Frontal Fibrosing Alopecia and lupus erythematosus in a patient may suggest a shared pathogenic background.
8 citations
,
January 2011 in “Korean Journal of Andrology” This study found that combining 4 mg doxazosin with 0.2 mg tamsulosin improved urinary symptoms with fewer vasodilatory side effects compared to a higher dose of doxazosin in hypertensive males with LUTS.
January 2025 in “KeiO Associated Repository of Academic Resources (Keio University)” Stronger regulations and protections are needed for digital platforms to ensure safety and fairness in health, education, and labor.